Loading…
Loading…
As of 20 Nov 2026: CCME Global ₹35.19 (m-cap ₹159 Cr) vs ENNATURE ₹167.65 (m-cap ₹374 Cr, P/E 373.9). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | CCME Global | ENNATURE |
|---|---|---|
| Share price | ₹35.19 | ₹167.65 |
| Day change | −4.99% | −6.03% |
| Market cap | ₹159 Cr | ₹374 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | — | 373.9 |
| P/BPrice ÷ book value per share. | 4.0 | — |
| ROEReturn on equity. | -2.9% | — |
| ROCEReturn on capital employed. | -2.9% | — |
| Sales growth (3Y CAGR) | — | — |
| Profit growth (3Y CAGR) | — | — |
| Debt to equity | 0.00 | 0.00 |
| Dividend yield | 0.00% | 0.00% |
| 1-year price return | −78.2% | — |
| Promoter holding | 74.4% | 59.6% |
| Industry | Biotechnology | Biotechnology |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Ennature Bio Pharma Ltd is larger, with a market cap of ₹374 Cr against ₹159 Cr for CCME Global Ltd as of 20 Nov 2026 — about 2.3 times the size.
CCME Global Ltd has no meaningful P/E right now (a loss over the last twelve months, or no reported earnings), so the two cannot be compared on P/E.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.